ClinicalTrials.gg
TerminatedNCT05267106FIGHT-209Updated Dec 30, 2025Results posted

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

A Phase 2 interventional study of Pemigatinib in Glioblastoma and Adult-type Diffuse Gliomas, sponsored by Incyte Corporation. Terminated at 79 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
198th of 1,155
83 · median 33
Started
2022
with 56 others
Phase 2
396 of 1,302
37 open now
Registered
1,079th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 198th largest by enrollment of the 1,155 interventional ones that give a count, is one of 57 that started in 2022, is one of 396 in phase 2, and was the 1,079th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.

03

Conditions studied

  • Glioblastoma
  • Adult-type Diffuse Gliomas

Keywords

  • glioblastoma
  • GBM
  • adult-type diffuse gliomas
  • gliomas
  • oligodendroglioma
  • FGFR1-3 Alteration
  • FGFR1-3 fusions
  • FGFR1-3 rearrangements
  • Central nervous system tumor
  • isocitrate dehydrogenase
  • IDH-mutant astocytoma
  • IDH-wild-type GBM
  • glioneuronal
  • neuronal
  • circumscribed astrocytic glioma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological, cytological, or molecular confirmation of recurrent GBM or other glioma, circumscribed astrocytic glioma, or glioneuronalor neuronal tumors that has recurred.
  • Radiographically .

    . - performance status ≥ 60.

  • ≥ 12 weeks.
  • Documentation of an actionable FGFR1-3 gene mutation or fusion/rearrangement from tissue : FGFR1-3 fusions or other rearrangements (FGFR1-3 in-frame fusions, any FGFR2 rearrangement, or FGFR1/3 rearrangement with known partner) or a defined FGFR1-3 activating mutation or in-frame deletion. Only participants with FGFR fusions or rearrangements with an intact kinase domain are eligible.
  • MRI-documented objective progression after prior therapy and must have no therapy available that is likely to provide clinical benefit.
  • Most recent must be a tumor block or a minimum of 15 unstained slides from biopsy or resection of primary tumor or .
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of an FGFR inhibitor.
  • Receipt of anticancer medications or drugs for any indication or reason within 28 days before first dose of study drug.
  • Participants may have had treatment for an unlimited number of prior relapses but must not have had prior bevacizumab or other VEGF/VEGFR inhibitors (exception: prior bevacizumab is allowed if it was administered for the treatment of radiation necrosis rather than progressive tumor and was stopped at least 12 weeks prior to MRI showing tumor progression).
  • Concurrent anticancer therapy
  • Candidate for potentially curative surgery.
  • Dexamethasone (or equivalent) > 4 mg daily at the time of study registration
  • Current evidence of corneal or retinal disorder as confirmed by ophthalmologic examination.
  • Diffuse .
  • Radiation therapy administered within 12 weeks before enrollment/first dose of study drug.
  • Known additional that is progressing or requires active systemic treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Cohort A: IDH-wild-type GBM

    Participants with histopathologically proven, WHO Grade 4, IDH-wild-type GBM OR molecular diagnosis of IDH-wild-type, diffuse astrocytic glioma with molecular features of Grade 4 GBM that are recurrent, harboring FGFR1-3 fusions/or other rearrangements, or with a defined FGFR1-3 mutation or in-frame deletion.

    Drug: Pemigatinib

  • Experimental
    Cohort B: Other gliomas other than GBM

    Participants with other histopathologically proven gliomas other than GBM, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors that are recurrent, harboring FGFR1-3 fusions/or other rearrangements or with a defined FGFR1-3 activating mutation or in-frame deletion

    Drug: Pemigatinib

Interventions

  • 13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.

    Also known as: NCB054828

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants With Recurrent Glioblastoma Based on Independent Central Review

    ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) based on Response Assessment in Neuro-Oncology (RANO) as determined by an independent centralized radiological review committee. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

    Time frame: up to 651 days

Secondary outcomes

  1. ORR in Participants With Recurrent Non-glioblastoma Central Nervous System Tumors Based on Independent Central Review

    ORR was defined as the percentage of participants who achieved a best overall response of CR or PR based on RANO as determined by an independent centralized radiological review committee. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

    Time frame: up to 784 days

  2. Duration of Confirmed Response Based on Independent Central Review

    Duration of response was defined as the time from the first assessment of confirmed CR or PR until progressive disease (PD) (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

    Time frame: up to 784 days

  3. Duration of Unconfirmed Response Based on Independent Central Review

    Duration of response was defined as the time from the first assessment of unconfirmed CR or PR until progressive disease (PD) (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

    Time frame: up to 784 days

  4. ORR as Determined by Investigator Assessment

    ORR was defined as the percentage of participants who achieved an unconfirmed best overall response of CR or PR based on RANO as determined by investigator assessment. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

    Time frame: up to 784 days

  5. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

    Time frame: up to 814 days

  6. Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 814 days

  7. Number of Participants With TEAEs Leading to Discontinuation of Pemigatinib, Pemigatinib Dose Interruption, and Pemigatinib Dose Reduction

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

    Time frame: up to 814 days

  8. Disease Control Rate (DCR) Based on Independent Central Review

    DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) based on RANO as determined by an independent centralized radiological review committee. In the case of SD, measurements must have met the SD criteria after the date of the first dose at a minimum interval of 42 days. SD occurred if the participant didn't qualify for CR, PR, or PD and required the following: stable nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan and clinically stable status.

    Time frame: up to 784 days

  9. Progression-free Survival (PFS) Based on Independent Central Review

    PFS was defined as the time from the first dose until progressive disease (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

    Time frame: up to 784 days

  10. Overall Survival

    Overall survival was defined as the time from the first dose of study drug to death due to any cause.

    Time frame: up to 784 days

07

Results

Posted Dec 30, 2025
Limitations and caveats
The study was terminated by the sponsor after the prespecified interim analysis did not meet the futility boundary.

Participant flow

Participant flow — Overall Study
MilestoneRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Started749
Completed00
Not completed749
Withdrew: Death502
Withdrew: Study terminated by sponsor246
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryObjective Response Rate (ORR) in Participants With Recurrent Glioblastoma Based on Independent Central Review

ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) based on Response Assessment in Neuro-Oncology (RANO) as determined by an independent centralized radiological review committee. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

Time frame:
up to 651 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) in Participants With Recurrent Glioblastoma Based on Independent Central Review
percentage of participantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Confirmed tumor responses5.4 (1.49 to 13.27)—
Unconfirmed tumor responses8.1 (3.03 to 16.82)—
SecondaryORR in Participants With Recurrent Non-glioblastoma Central Nervous System Tumors Based on Independent Central Review

ORR was defined as the percentage of participants who achieved a best overall response of CR or PR based on RANO as determined by an independent centralized radiological review committee. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

Time frame:
up to 784 days
Reported as:
Number · percentage of participants
ORR in Participants With Recurrent Non-glioblastoma Central Nervous System Tumors Based on Independent Central Review
percentage of participantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Confirmed tumor responses—22.2 (2.81 to 60.01)
Unconfirmed tumor responses—22.2 (2.81 to 60.01)
SecondaryDuration of Confirmed Response Based on Independent Central Review

Duration of response was defined as the time from the first assessment of confirmed CR or PR until progressive disease (PD) (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

Time frame:
up to 784 days
Reported as:
Median · months
Duration of Confirmed Response Based on Independent Central Review
monthsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Duration of Confirmed Response Based on Independent Central ReviewNA (NA to NA)NA (NA to NA)
SecondaryDuration of Unconfirmed Response Based on Independent Central Review

Duration of response was defined as the time from the first assessment of unconfirmed CR or PR until progressive disease (PD) (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

Time frame:
up to 784 days
Reported as:
Median · months
Duration of Unconfirmed Response Based on Independent Central Review
monthsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Duration of Unconfirmed Response Based on Independent Central ReviewNA (1.74 to NA)NA (NA to NA)
SecondaryORR as Determined by Investigator Assessment

ORR was defined as the percentage of participants who achieved an unconfirmed best overall response of CR or PR based on RANO as determined by investigator assessment. CR requires all of the following: disappearance of all enhancing measurable/nonmeasurable disease sustained for ≥4 weeks; no new lesions; stable/improved nonenhancing lesions; off corticosteroids/on physiologic replacement doses only and stable/improved clinically. PR requires all of the following: ≥50% decrease, compared with baseline, in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for ≥4 weeks; no progression of nonmeasurable disease; no new lesions; stable or improved nonenhancing lesions on same/lower dose of corticosteroids compared with baseline scan; on a corticosteroid dose not greater than the dose at time of baseline scan and stable/improved clinically.

Time frame:
up to 784 days
Reported as:
Number · percentage of participants
ORR as Determined by Investigator Assessment
percentage of participantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
ORR as Determined by Investigator Assessment8.1 (3.03 to 16.82)22.2 (2.81 to 60.01)
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

Time frame:
up to 814 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)739
SecondaryNumber of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 814 days
Reported as:
Count of participants · Participants
Number of Participants With Any ≥Grade 3 TEAE
ParticipantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Number of Participants With Any ≥Grade 3 TEAE273
SecondaryNumber of Participants With TEAEs Leading to Discontinuation of Pemigatinib, Pemigatinib Dose Interruption, and Pemigatinib Dose Reduction

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as an AE reported for the first time or the worsening of a pre-existing event after the first dose of pemigatinib and within 30 days of the last dose of pemigatinib.

Time frame:
up to 814 days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Discontinuation of Pemigatinib, Pemigatinib Dose Interruption, and Pemigatinib Dose Reduction
ParticipantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
TEAEs leading to discontinuation of pemigatinib20
TEAEs leading to pemigatinib dose interruption224
TEAEs leading to pemigatinib dose reduction52
SecondaryDisease Control Rate (DCR) Based on Independent Central Review

DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) based on RANO as determined by an independent centralized radiological review committee. In the case of SD, measurements must have met the SD criteria after the date of the first dose at a minimum interval of 42 days. SD occurred if the participant didn't qualify for CR, PR, or PD and required the following: stable nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan and clinically stable status.

Time frame:
up to 784 days
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Based on Independent Central Review
percentage of participantsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Confirmed tumor responses36.5 (25.60 to 48.49)66.7 (29.93 to 92.51)
Unconfirmed tumor responses36.5 (25.60 to 48.49)66.7 (29.93 to 92.51)
SecondaryProgression-free Survival (PFS) Based on Independent Central Review

PFS was defined as the time from the first dose until progressive disease (according to RANO and assessed by an independent centralized radiological review committee) or death (whichever occurred first). Progression was defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor, or to decrease in corticosteroid dose.

Time frame:
up to 784 days
Reported as:
Median · months
Progression-free Survival (PFS) Based on Independent Central Review
monthsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Progression-free Survival (PFS) Based on Independent Central Review2.07 (2.04 to 2.37)NA (1.74 to NA)
SecondaryOverall Survival

Overall survival was defined as the time from the first dose of study drug to death due to any cause.

Time frame:
up to 784 days
Reported as:
Median · months
Overall Survival
monthsRecurrent GlioblastomaRecurrent Non-glioblastoma CNS Tumors
Overall Survival11.37 (9.23 to 14.85)24.08 (18.79 to NA)

Adverse events

Collected over up to 814 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recurrent Glioblastoma50/74 (67.6%)17/74 (23%)71/74 (95.9%)
Recurrent Non-glioblastoma CNS Tumors2/9 (22.2%)0/9 (0%)9/9 (100%)
Total52/83 (62.7%)17/83 (20.5%)80/83 (96.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventRecurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
Confusional statePsychiatric disorders2/740/92/83
HemiparesisNervous system disorders2/740/92/83
PneumoniaInfections and infestations2/740/92/83
SeizureNervous system disorders2/740/92/83
Urinary tract infectionInfections and infestations2/740/92/83
Acute kidney injuryRenal and urinary disorders1/740/91/83
AphasiaNervous system disorders1/740/91/83
AstheniaGeneral disorders1/740/91/83
Cognitive disorderNervous system disorders1/740/91/83
EpilepsyNervous system disorders1/740/91/83
Most frequent other events
Showing 10 of 106
Most frequent other events
EventRecurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
DiarrhoeaGastrointestinal disorders33/748/941/83
AlopeciaSkin and subcutaneous tissue disorders16/747/923/83
HyperphosphataemiaMetabolism and nutrition disorders54/747/961/83
Dry skinSkin and subcutaneous tissue disorders11/745/916/83
ConstipationGastrointestinal disorders16/744/920/83
HypophosphataemiaMetabolism and nutrition disorders16/744/920/83
OnycholysisSkin and subcutaneous tissue disorders4/744/98/83
Dry eyeEye disorders8/743/911/83
Dry mouthGastrointestinal disorders10/743/913/83
FatigueGeneral disorders21/743/924/83

Baseline characteristics

Age, Continuous
Age, Continuous(years)Recurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
Mean57.0 ± 11.4539.2 ± 12.7555.1 ± 12.79
Sex: Female, Male
Sex: Female, Male(Participants)Recurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
Female30333
Male44650
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Recurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
Hispanic or Latino101
Not Hispanic or Latino60666
Unknown or Not Reported13316
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Recurrent GlioblastomaRecurrent Non-glioblastoma CNS TumorsTotal
White/Caucasian58664
Black/African-American202
Asian202
Not Reported718
Unknown516
Captured as "Other" in Database011
08

Study locations

79 sites
  • Valkyrie Clinical Trials
    Beverly Hills, California 90211, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Usc Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Stanford Neuroscience Health Center
    Sacramento, California 94304, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Providence St Joseph Hospital Orange Center For Cancer Prevention and Treatment
    Santa Monica, California 90404, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510-3220, United States
  • Baptist Md Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Orlando Health Cancer Institute Downtown Orlando
    Orlando, Florida 32806, United States
  • H. Lee Moffitt Cancer Center and Research Institute Hospital
    Tampa, Florida 33612, United States
  • University of Illinois Hospital & Health Sciences System
    Chicago, Illinois 60612, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa 52242, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • University of Minnesota Health Clinics and Surgery Center
    Minneapolis, Minnesota 55455, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • UC Health At Cincinnati Va Medical Center
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center Health System
    Pittsburgh, Pennsylvania 15232, United States
  • Tennessee Oncology
    Chattanooga, Tennessee 37403, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Aalborg Universitets Hospital
    Aalborg, 09000, Denmark
  • Rigshospitalet Uni of Hospital of Copenhagen
    Copenhagen, 02100, Denmark
  • Odense University Hospital
    Odense C, 05000, Denmark
  • Chru de Lille Hopital Claude Huriez
    Lille, 59037, France
  • Chu Hopital de La Timone
    Marseille, 13005, France
  • Hospital Universitaire Pitie-Salpetriere
    Paris, 75013, France
  • Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
    Toulouse, 31059, France
  • Universitatsklinikum Bonn Aoer
    Bonn, 53127, Germany
  • Klinikum Der Johann Wolfgang Goethe University
    Frankfurt, 60528, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • University Hospital Tuebingen
    Tübingen, 72076, Germany
  • Ospedale Bellaria
    Bologna, 40139, Italy
  • Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
    Milan, 20132, Italy
  • Iov - Istituto Oncologico Veneto Irccs
    Padova, 35128, Italy
  • A.S.L. Napoli 1 Centro Ospedale Del Mare
    Ponticelli, 80147, Italy
  • Irccs Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza
    Torino, 10124, Italy
  • University of Tokyo Hospital
    Bunkyō City, 113-8655, Japan
  • National Cancer Center Hospital
    Chūōku, 104-0045, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
  • Nagoya University Hospital
    Nagoya, 466-8560, Japan
  • Tohoku University Hospital
    Sendai, 980-8574, Japan
  • Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis
    Amsterdam, 1066 CX, Netherlands
  • Erasmus Mc Cancer Institute
    Rotterdam, 3015 GD, Netherlands
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Hospital General Universitario Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic Barcelona Main
    Barcelona, 08036, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Ico Girona Hospital Universitari de Girona Dr Josep Trueta
    Girona, 17007, Spain
  • Ico Institut Catala D Oncologia
    L'Hospitalet de Llobregat, 08908, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Hm Sanchinarro
    Madrid, 28050, Spain
  • Clinica Universidad de Navarra (Cun)
    Pamplona, 31008, Spain
  • Hospital General de Catalunya
    Sant Cugat del Vallès, 08190, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Addenbrooke'S Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Velindre Cancer Centre
    Cardiff, CF14 2TL, United Kingdom
  • St James'S University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Guys Hospital
    London, SE1 9RT, United Kingdom
  • The Royal Marsden Nhs Foundation Trust - Sutton
    London, SW3 6JJ, United Kingdom
  • The Royal Marsden Nhs Foundation Trust - Chelsea
    London, SW36JJ, United Kingdom
  • The Christie Nhs Foundation Trust Uk
    Manchester, M20 4BX, United Kingdom
  • The Clatterbridge Cancer Centre
    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2024, 30 months.

Results were first posted in Dec 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Mar 4, 2022
StartActual
May 20, 2022
Primary completionActual
Dec 17, 2024
CompletionActual
Dec 17, 2024
Results first posted
Dec 30, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05267106
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
May 20, 2022
Primary completion
Dec 17, 2024
Completion
Dec 17, 2024
Results posted
Dec 30, 2025
Last update
Dec 30, 2025

Study contacts

Victoria Ebiana, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion